217 related articles for article (PubMed ID: 35174500)
1. Identification of a novel probiotic and its protective effects on NAFLD via modulating gut microbial community.
Geng W; Zhang Y; Yang J; Zhang J; Zhao J; Wang J; Jia L; Wang Y
J Sci Food Agric; 2022 Aug; 102(11):4620-4628. PubMed ID: 35174500
[TBL] [Abstract][Full Text] [Related]
2. Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression.
Zhou Y; Zheng T; Chen H; Li Y; Huang H; Chen W; Du Y; He J; Li Y; Cao J; Nie Y; Zhou Y
Cell Physiol Biochem; 2018; 51(5):2123-2135. PubMed ID: 30522122
[TBL] [Abstract][Full Text] [Related]
3. Mussel polysaccharide α-D-glucan (MP-A) protects against non-alcoholic fatty liver disease via maintaining the homeostasis of gut microbiota and regulating related gut-liver axis signaling pathways.
Wu J; Shao H; Zhang J; Ying Y; Cheng Y; Zhao D; Dou X; Lv H; Li S; Liu F; Ling P
Int J Biol Macromol; 2019 Jun; 130():68-78. PubMed ID: 30797009
[TBL] [Abstract][Full Text] [Related]
4. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
[TBL] [Abstract][Full Text] [Related]
5. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
[TBL] [Abstract][Full Text] [Related]
6. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
8. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
9. Combination of Probiotics and
Wang W; Xu AL; Li ZC; Li Y; Xu SF; Sang HC; Zhi F
Diabetes Metab J; 2020 Apr; 44(2):336-348. PubMed ID: 31950772
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
11. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
12. Supplementation with Lactobacillus kefiranofaciens ZW3 from Tibetan Kefir improves depression-like behavior in stressed mice by modulating the gut microbiota.
Sun Y; Geng W; Pan Y; Wang J; Xiao P; Wang Y
Food Funct; 2019 Feb; 10(2):925-937. PubMed ID: 30698577
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
14. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
15. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Wang P; Wang J; Li D; Ke W; Chen F; Hu X
J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
[TBL] [Abstract][Full Text] [Related]
16. Role of Probiotics in Gut Microbiome and Metabolome in Non-Alcoholic Fatty Liver Disease Mouse Model: A Comparative Study.
Wu T; Zeng Z; Yu Y
Microorganisms; 2024 May; 12(5):. PubMed ID: 38792849
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of Probiotics in the Management of NAFLD: Evidence and Involved Mechanisms of Action from Preclinical and Human Models.
Arellano-García L; Portillo MP; Martínez JA; Milton-Laskibar I
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328587
[TBL] [Abstract][Full Text] [Related]
18. Specific Strains of
Hu W; Gao W; Liu Z; Fang Z; Wang H; Zhao J; Zhang H; Lu W; Chen W
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889903
[TBL] [Abstract][Full Text] [Related]
19. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats.
Zhong M; Yan Y; Yuan H; A R; Xu G; Cai F; Yang Y; Wang Y; Zhang W
Food Funct; 2022 Jul; 13(13):7287-7301. PubMed ID: 35726797
[TBL] [Abstract][Full Text] [Related]
20. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.
Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
